Eyestem’s Eyecyte-RPE™ Trial Shows Vision Rescue for Geographic Atrophy Patients
All nine subjects of phase 1 injected without any serious adverse events.
Category: Healthcare & Pharmaceuticals
Pfizer Announces Development Discontinuation of Danuglipron an Oral GLP-1 Receptor Agonist
Data from the danuglipron clinical development program will be presented at a scientific meeting or published in a peer-reviewed journal in the future.
Sanofi’s Investigational New Drug Tolebrutinib for Multiple Sclerosis Shows Positive Results in Phase 3 Trials
Tolebrutinib was generally well tolerated by all subjects across all study arms.
Amgen’s IMDELLTRA® Phase 3 Trials Demonstrated Superior Overall Survival in Small Cell Lung Cancer
IMDELLTRA’s safety profile was consistent with the recognized profile. Detailed DeLLphi-304 results will be presented at an upcoming medical congress.
U.S. FDA to Phase Out Animal Testing for the Development of Monoclonal Antibodies and Other Drugs
The FDA’s animal testing requirement will be decreased, modified, or potentially replaced utilizing a variety of methodologies.
mAb Capture Made Cost Effective and Productive With Cytiva’s Protein A Resins
A one-size-fits-all strategy to protein purification is no longer practicable, given the development and transformation of the mAb market, notably the recent rapid emergence of [Read More…]
Ozempic® Results from STRIDE Shown to Improve Walking Distance and Quality of Life in Adults With Type 2 Diabetes and Peripheral Artery Disease (PAD)
Novo Nordisk presented the full results of STRIDE, a phase 3b peripheral artery disease (PAD) outcomes trial that looked at the effects of once-weekly injectable Ozempic®.
U.S. FDA Approved Amgen’s UPLIZNA® (INEBILIZUMAB-CDON) for the Treatment of Rare Immune Disorder
IgG4-RD can arise in various organs, causing fibrosis and irreversible organ damage. Understanding how organ damage occurs is key to making an accurate diagnosis of IgG4-RD.
New Vaccination Concept Targets Dangerous Bacteria in the Intestine
For a long time, scientists have been looking into vaccines against pathogenic bacteria in the bowel, particularly those that drugs have proved ineffective against due to resistance.
Aldeyra Therapeutics Responds to the U.S. FDA’s Denial of Reproxalap’s NDA Application for Treating Signs and Symptoms of Dry Eye Disease
FDA stated in the letter that the NDA “failed to demonstrate efficacy in adequate and well controlled studies in treating ocular symptoms associated with dry eyes”.
